| Literature DB >> 25145671 |
Meritxell Rosell1, Ekaterina Nevedomskaya2, Suzan Stelloo3, Jaya Nautiyal1, Ariel Poliandri1, Jennifer H Steel1, Lodewyk F A Wessels4, Jason S Carroll5, Malcolm G Parker1, Wilbert Zwart6.
Abstract
RIP140 is a transcriptional coregulator involved in energy homeostasis, ovulation, and mammary gland development. Although conclusive evidence is lacking, reports have implicated a role for RIP140 in breast cancer. Here, we explored the mechanistic role of RIP140 in breast cancer and its involvement in estrogen receptor α (ERα) transcriptional regulation of gene expression. Using ChIP-seq analysis, we demonstrate that RIP140 shares more than 80% of its binding sites with ERα, colocalizing with its interaction partners FOXA1, GATA3, p300, CBP, and p160 family members at H3K4me1-demarcated enhancer regions. RIP140 is required for ERα-complex formation, ERα-mediated gene expression, and ERα-dependent breast cancer cell proliferation. Genes affected following RIP140 silencing could be used to stratify tamoxifen-treated breast cancer cohorts, based on clinical outcome. Importantly, this gene signature was only effective in endocrine-treated conditions. Cumulatively, our data suggest that RIP140 plays an important role in ERα-mediated transcriptional regulation in breast cancer and response to tamoxifen treatment. ©2014 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25145671 DOI: 10.1158/0008-5472.CAN-13-3429
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701